Commitments and Contingent Liabilities (Details Narrative) - Chemomab Therapeutics Ltd [Member] - USD ($) $ in Thousands |
12 Months Ended | ||||
|---|---|---|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
Dec. 31, 2022 |
Dec. 29, 2024 |
|
| Long-Term Purchase Commitment [Line Items] | |||||
| Licensed product payment | $ 300 | ||||
| Decsription of occurrence for payments | upon the occurrence of either (i) closing of a public offering of the ordinary shares of Chemomab; or (ii) a Change of Control Transaction, Chemomab shall pay the Fund a cash payment equal to one percent (1%) of the proceeds raised by Chemomab in its initial public offering, or 1% of the consideration received by Chemomab or its shareholders at the closing of a Change of Control Transaction (after deduction of amounts paid as liquidation preference to the shareholders of Chemomab on account of their investment in Chemomab, if any), but in any event not more than $3,000 thousand | ||||
| Maximum percentage of payments of royalties | 100.00% | ||||
| Cumulative amounts of grants received | $ 1,227 | ||||
| Royality expenses | 1,018 | $ 418 | $ 4,832 | ||
| Advances to subcontractor | $ 2,432 | 968 | |||
| Bank restricted deposit | $ 76 | ||||
| Accretion expense | $ 638 | ||||
| Accrued income taxes | $ 538 | ||||
| New Drug Applicationand Biological License Application [Member] | |||||
| Long-Term Purchase Commitment [Line Items] | |||||
| Description of application payment for licensed product | $100 thousands upon submission of a New Drug Application (“NDA”), Biological License Application (“BLA”) or equivalent for each Licensed Product to the United States Food and Drug Administration (“FDA”), $100 thousands upon submission of a similar application for each | ||||
| Royalty payments on sale of product | 3.00% | ||||
| Capital Additions One [Member] | |||||
| Long-Term Purchase Commitment [Line Items] | |||||
| Description of application payment for licensed product | $200 thousands upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per Licensed Product, provided that for each jurisdiction, payment shall be made only once | ||||